This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
by Zacks Equity Research
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
by Zacks Equity Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
by Zacks Equity Research
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study
by Zacks Equity Research
CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down
by Zacks Equity Research
Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
by Zacks Equity Research
Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
by Zacks Equity Research
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.
Intercept (ICPT) Posts New Positive Results on NASH Drug
by Zacks Equity Research
Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.
Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.
Intercept Slumps as the FDA Issues CRL to NASH Candidate
by Zacks Equity Research
Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
How Galmed (GLMD) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for December 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 4th
NASH Scorecard Year to Date: The Winners and the Losers
by Ekta Bagri
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
by Zacks Equity Research
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
Novan Announces Top-Line Data From Mid-Stage Molluscum Study
by Zacks Equity Research
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Galmed Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 64.29% and 400.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?